Hum. Reprod. Advance Access published online on October 24, 2006
Human Reproduction, doi:10.1093/humrep/del395
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1 Endocrinology Unit, Hospital Sant Joan de Déu, University of Barcelona, Spain
* To whom correspondence should be addressed. BACKGROUND: In 1998, we revealed a sequence departing from prenatal growth restraint in girls and evolving, through precocious pubarche (PP) in mid-childhood, towards anovulatory and hyperinsulinaemic hyperandrogenism. The latter condition fulfilled the criteria for the diagnosis of polycystic ovary syndrome (PCOS), which was then defined independently of the presence of polycystic ovaries (PCOs). Since 2003, the diagnosis of PCOS has been extended by adding PCO as an alternative criterion. We verified longitudinally over 28 ± 2 years the prevalence of PCO and its potential relationship to growth before birth in a group of post-PP women (n = 14, mean age = 28 years; body mass index = 24.3 kg/m2) belonging to the original cohort of 35 girls in whom the PP-PCOS sequence was described. METHODS: Endocrine-metabolic variables, body composition (by dual-energy X-ray absorptiometry), carotid intima-media thickness (IMT) and ovarian morphology by transvaginal ultrasonography were assessed in all women. RESULTS: Post-PP women with a birthweight (BW) in the lowest quartile, when compared with post-PP women with a higher BW, had smaller ovaries (mean volume = 4.0 versus 9.0 ml; P = 0.004) and a much lower prevalence of PCO (0 versus 67%; P = 0.006). The remaining variables were similar between BW subgroups. CONCLUSIONS: The presence of a PCO morphology in women with a PP history was found to relate to prenatal growth. It would be of interest to verify whether a similar relationship exists in anovulatory and/or hyperandrogenic women without PP history.
Received June 8, 2006
Revised July 29, 2006
Accepted August 9, 2006
Article
Polycystic ovaries after precocious pubarche: relation to prenatal growth
L. Ibáñez 1 *, A. Jaramillo 2, G. Enríquez 3, E. Miró 4, A. López-Bermejo 5, D. Dunger 6, and F. de Zegher 7
2 Endocrinology Unit, Hospital Sant Joan de Déu, University of Barcelona, Girona, Spain
3 Department of Radiology, Hospital Materno-Infantil Vall d’Hebron, Autonomous University of Barcelona, Spain
4 Department of Gynecology, Hospital Sant Joan de Déu, University of Barcelona, Spain
5 Diabetes, Endocrinology and Nutrition Unit, Dr Josep Trueta Hospital, Girona, Spain
6 Department of Paediatrics, University of Cambridge, Cambridge, UK
7 Department of Woman and Child, University of Leuven, Leuven, Belgium
L. Ibáñez, E-mail: libanez{at}hsjdbcn.org
Abstract 
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  Y. B. Sverrisdottir, T. Mogren, J. Kataoka, P. O. Janson, and E. Stener-Victorin Is polycystic ovary syndrome associated with high sympathetic nerve activity and size at birth? Am J Physiol Endocrinol Metab, March 1, 2008; 294(3): E576 - E581. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Ibanez, A. Lopez-Bermejo, J. Callejo, A. Torres, S. Cabre, D. Dunger, and F. de Zegher Polycystic Ovaries in Nonobese Adolescents and Young Women with Ovarian Androgen Excess: Relation to Prenatal Growth J. Clin. Endocrinol. Metab., January 1, 2008; 93(1): 196 - 199. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Ibanez, A. Lopez-Bermejo, L. del Rio, G. Enriquez, C. Valls, and F. de Zegher Combined Low-Dose Pioglitazone, Flutamide, and Metformin for Women with Androgen Excess J. Clin. Endocrinol. Metab., May 1, 2007; 92(5): 1710 - 1714. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. L. Rosenfield Identifying Children at Risk for Polycystic Ovary Syndrome J. Clin. Endocrinol. Metab., March 1, 2007; 92(3): 787 - 796. [Abstract] [Full Text] [PDF]
|
|